This inventor holds 3 USPTO granted patents. Top assignee: Pfizer Corporation. Active years: 2003-2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Oxford, OH (US) (2003)
- Mystic, CT (US) (2005 - 2006)
Company Filing History:
Years Active: 2003-2006
Title: The Innovative Contributions of Anthony R. Reinhold
Introduction
Anthony R. Reinhold is a notable inventor based in Mystic, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that address various neurological disorders. With a total of 3 patents to his name, Reinhold's work has the potential to impact the treatment of central and peripheral nervous system disorders.
Latest Patents
Reinhold's latest patents include innovative compounds such as acylamino cyclopropane derivatives and thieno-pyrimidin-4-one AMPA antagonists. The acylamino cyclopropane derivatives represent a novel approach in pharmaceutical chemistry. The thieno-pyrimidin-4-one AMPA antagonists are particularly noteworthy, as they relate to novel quinazolin-4-one derivatives that can be used in pharmaceutical compositions. These compounds are designed to treat neurodegenerative, psychotropic, and drug and alcohol-induced disorders affecting the central and peripheral nervous systems.
Career Highlights
Reinhold is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to collaborate with some of the brightest minds in the industry, further enhancing his contributions to medical science.
Collaborations
Among his notable coworkers are Bertrand Leo Chenard and Willard McKowan Welch, Jr. Their collaboration has fostered an environment of innovation and creativity, leading to advancements in pharmaceutical research.
Conclusion
Anthony R. Reinhold's innovative work in the pharmaceutical field exemplifies the impact of dedicated inventors on medical science. His contributions through patents and collaborations continue to pave the way for new treatments and therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
